Adicet Bio, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Adicet Bio, Inc. is a clinical-stage biotechnology company that develops allogeneic gamma delta T cell therapies designed to treat autoimmune diseases and various cancers. Its primary products include engineered gamma delta T cells with chimeric antigen receptors (CARs) that enhance immune targeting and durable activity. The company’s lead product candidate, ADI-001, is an allogeneic gamma delta CAR T cell therapy targeting CD20, currently in Phase 1 clinical trials for autoimmune diseases such as lupus nephritis and relapsed/refractory B-cell non-Hodgkin’s lymphoma. Adicet also develops ADI-270, an armored gamma delta CAR T cell product candidate targeting CD70 for multiple solid tumors and hematological malignancies, including renal cell carcinoma. The company operates primarily in the United States and focuses on oncology and immunology sectors by harnessing gamma delta T cells' innate tumor-targeting capabilities. Founded in 2014 and headquartered in Boston, Massachusetts, Adicet Bio’s business model centers on off-the-shelf allogeneic cell therapies, aiming to provide accessible and effective treatments. The company has established strategic partnerships, including one with MaxCyte, which enhances its manufacturing capabilities through proprietary non-viral gene editing technologies. Recently, it completed a $74.8 million net financing extending its cash runway into the second half of 2027, supporting ongoing clinical development and manufacturing scale-up. In 2025, Adicet reported positive preliminary Phase 1 data for ADI-001 in autoimmune diseases, demonstrating rapid reductions in disease activity and improved renal function with favorable safety profiles. It initiated a Phase 1 trial for rheumatoid arthritis and plans to start a pivotal ADI-001 study in 2026 following an FDA meeting. These recent developments underscore Adicet’s expanded pipeline and strategic focus on autoimmune disorders and oncology. Adicet Bio’s innovative platform leverages the unique biological properties of gamma delta T cells to target solid tumors and hematologic cancers with novel specificity and improved safety margins compared to traditional alpha beta T cell therapies. Its therapies are engineered for availability on demand and best-in-class drug exposure, addressing unmet medical needs globally. The company maintains ongoing clinical and preclinical programs to expand its pipeline and advance the cell therapy field, highlighting its commitment to transforming treatment landscapes in oncology and autoimmune diseases through scientific and manufacturing excellence.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $69.00
Adicet Bio, Inc. (NASDAQ:ACET) Receives $69.00 Consensus PT from Brokerages
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Adicet Bio (NASDAQ:ACET) Shares Pass Below 200-Day Moving Average – What’s Next?
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Down 95.7% in December
Adicet Bio (NASDAQ:ACET) Stock Passes Below Two Hundred Day Moving Average – Should You Sell?
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update
Adicet Bio Announces Reverse Stock Split
Adicet Bio (NASDAQ:ACET) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $7.33
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference